Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVd-Lite in newly diagnosed stage III AL amyloidosis
ChiCTR2500103075Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daratumumab, bortezomib, dexamethasone and prednisone in light-chain amyloidosis, sponsored by West China Hospital of Sichuan University. Primary endpoints: Overall survival and Progression-free survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
daratumumabbortezomibdexamethasoneprednisone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ChiCTR2500103075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103075.